International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7844676
Original Article
Association of Clinical Profile and Demographic Factors Associated with the Adverse Outcomes in Elderly with Covid-19 Infection in a Tertiary Care Hospital
 ,
 ,
 ,
 ,
 ,
Published
April 19, 2023
Abstract
INTRODUCTION: Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities. Also, course of disease tends to be more severe in case of elderly resulting in higher mortality. MATERIALS AND METHODS: This retrospective study included 757 admitted covid-19 patients in a dedicated tertiary care hospital. The data was collected between December 2021 to March 2022 were analysed for the clinical profile, demographic factors with adverse outcomes in elderly patients. RESULTS: 308 were elderly patients, Mean age was 70.2,males-190(61.7%) females118(38.3%), 267(86.7%) were discharged,40 (13%) died,1(0.3%) went dama.6(1.9%) were asymptomatic,131(42.5%) had mild disease,128(41.6) had moderate disease , 43(14%) had severe disease. 52(16.9%) were vaccinated with covaxin,166(53.9%) were vaccinated with covishield, 90(29.2%) were not vaccinated. Diabetes(62%) and hypertension(53.9) were the major risk factors. Other risk factors included ischemic heart disease, chronic kidney disease, chronic obstructive pulmonary disease, seizures, pulmonary tuberculosis. CONCLUSION: The disease is more severe in patients with comorbidities and unvaccinated when compared to general population. Early diagnosis and individualized therapeutic management should be developed for elderly subjects based on personal medical history and comorbidities .
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1016 Views
461 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved